Pharmaxis has appointed PharmaSwiss, a division of Valeant Pharmaceuticals International, as distributor for Bronchitol (inhaled mannitol) in Poland and ten other Eastern European countries. The PharmaSwiss agreement forms part of Pharmaxis' commercialisation strategy, which to date has seen Bronchitol made available in the UK, Germany, Austria and Denmark and with pricing discussions soon to complete in France. PharmaSwiss will take responsibility for obtaining pricing approval with the Polish reimbursement authority, a process which is expected to take approximately 18 months to complete.
Other countries for which PharmaSwiss has been appointed distributor are Slovenia, Croatia, Serbia, Bosnia and Herzegovina, Montenegro, Macedonia, Latvia, Lithuania, Estonia and Kosovo.
Bronchitol has been developed to help clear mucus, improve lung function and reduce exacerbations in patients with cystic fibrosis (CF). It is a proprietary formulation of mannitol administered as a dry powder in a hand-held inhaler. Inhaled mannitol hydrates the lungs, helps restore normal lung clearance and allows patients to clear mucus more effectively. The product is approved for marketing for CF patients aged over six years in Australia and for patients aged 18 years and over throughout the EU. Bronchitol for CF is recently launched in Europe and Australia.